Medical Marijuana Inc (MJNA)

[FORU]

Medical Marijuana Secures Partnership with Key Pharmaceutical Distributor -- CFN Media

SEATTLE, WA--(Marketwired - Jan 18, 2017) - CFN Media Group, the leading creative agency and digital media network dedicated to legal cannabis, announces the publication of an article covering Medical Marijuana Inc.'s (OTC PINK: MJNA) recent groundbreaking agreement with a South American pharmaceutical distributor and how the company aims to capitalize on the market.

The hemp industry may be confronting some obstacles in the United States, but many Latin American countries have embraced the plant's potential. For instance, Mexico's COFEPRIS approved the impact of cannabidiol (CBD) oil for epilepsy treatment; Brazil's ANVISA legalized CBD for various therapeutic uses; and Chile approved a measure legalizing the cultivation and sale of medical marijuana last year and has since opened the largest marijuana farm in the region.

Over the past couple years, Medical Marijuana has set up several subsidiaries designed to distribute RSHO™ (the company's flagship CBD oil) outside of the United States. HempMedsPX™ LLC is a wholly owned subsidiary that distributes RSHO™ in Mexico and Puerto Rico using sub-distributors. HempMeds Brasil™ is a second 93.4% owned subsidiary focused on distributing RSHO™ in Brazil, which is the largest economy in South America and a significant end market for its products.

HempMeds® Brazil recently announced a partnership with Paragon HealthCare BR, a leading global wholesale distributor of pharmaceutical products that has relationships with medical professionals, doctor's groups, hospitals, pharmacists, and other health care providers. Paragon HealthCare also has several other businesses that serve customers around the world.

Under the terms of the agreement, Paragon HealthCare BR will make RSHO™ products accessible to those in need by assisting individuals in securing special importation permits. Over time, this will reduce the wait from prescription-to-delivery for patients that require CBDs to treat medical conditions. The distributor will also help facilitate medical research surrounding the applications of CBD in treating numerous medical conditions. With a wealth of doctors and clinics ready for such research, Paragon HealthCare BR is well positioned to help execute these studies and legitimize the use of non-psychoactive cannabinoids for neurological and other conditions. The good news is that Brazil and other countries are more open than the U.S. to such studies.

Please follow the link to read the full article: http://www.cannabisfn.com/medical-marijuana-secures-partnership-with-key-pharmaceutical-distributor/